Cargando…
A review of anabolic therapies for osteoporosis
Osteoporosis results from a loss of bone mass and bone structure such that the bone becomes weak and fractures with very little trauma. Until recently, the approved osteoporosis therapies prevented more bone loss by altering osteoclast activity and lifespan. Recently, attention has turned away from...
Autores principales: | , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2003
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC193734/ https://www.ncbi.nlm.nih.gov/pubmed/12932280 |
_version_ | 1782120914569134080 |
---|---|
author | Lane, Nancy E Kelman, Ariella |
author_facet | Lane, Nancy E Kelman, Ariella |
author_sort | Lane, Nancy E |
collection | PubMed |
description | Osteoporosis results from a loss of bone mass and bone structure such that the bone becomes weak and fractures with very little trauma. Until recently, the approved osteoporosis therapies prevented more bone loss by altering osteoclast activity and lifespan. Recently, attention has turned away from osteoclast inhibition to agents that can stimulate the osteoblast to form new bone, or anabolic agents. This article reviews both approved and experimental anabolic agents that improve bone mass by improving osteoblast activity, or increasing osteoblast number. The use of the anabolic agents to improve bone mass and strength followed by agents that prevent the new bone mass from being lost may offer the ability to cure osteoporosis and reduce bone fracture healing time. |
format | Text |
id | pubmed-193734 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2003 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-1937342003-09-15 A review of anabolic therapies for osteoporosis Lane, Nancy E Kelman, Ariella Arthritis Res Ther Review Osteoporosis results from a loss of bone mass and bone structure such that the bone becomes weak and fractures with very little trauma. Until recently, the approved osteoporosis therapies prevented more bone loss by altering osteoclast activity and lifespan. Recently, attention has turned away from osteoclast inhibition to agents that can stimulate the osteoblast to form new bone, or anabolic agents. This article reviews both approved and experimental anabolic agents that improve bone mass by improving osteoblast activity, or increasing osteoblast number. The use of the anabolic agents to improve bone mass and strength followed by agents that prevent the new bone mass from being lost may offer the ability to cure osteoporosis and reduce bone fracture healing time. BioMed Central 2003 2003-08-05 /pmc/articles/PMC193734/ /pubmed/12932280 Text en Copyright © 2003 BioMed Central Ltd |
spellingShingle | Review Lane, Nancy E Kelman, Ariella A review of anabolic therapies for osteoporosis |
title | A review of anabolic therapies for osteoporosis |
title_full | A review of anabolic therapies for osteoporosis |
title_fullStr | A review of anabolic therapies for osteoporosis |
title_full_unstemmed | A review of anabolic therapies for osteoporosis |
title_short | A review of anabolic therapies for osteoporosis |
title_sort | review of anabolic therapies for osteoporosis |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC193734/ https://www.ncbi.nlm.nih.gov/pubmed/12932280 |
work_keys_str_mv | AT lanenancye areviewofanabolictherapiesforosteoporosis AT kelmanariella areviewofanabolictherapiesforosteoporosis AT lanenancye reviewofanabolictherapiesforosteoporosis AT kelmanariella reviewofanabolictherapiesforosteoporosis |